Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMA3OWI)

• Drug Name: AZD4769 Drug Info
• Synonyms: Acetic acid, ((4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)-; 127481-29-2; L-674573; ((4-Phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)acetic acid; {[4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl]thio}acetic acid; L 674573; L-674,573; AC1L3YFJ; SCHEMBL9460146; CHEMBL422872; JOIXGLLMSDPZDN-UHFFFAOYSA-N; AZD-4769; 2-[[4-phenyl-1-[4-(2-quinolinylmethoxy)phenyl]butyl]thio]Acetic acid; DA-13018; FT-0734991; AZ-12096971; 2-[4-phenyl-1-[4-(quinolin-2-ylmethoxy)phenyl]butyl]sulfanylacetic

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 124437
  CAS Number: CAS 127481-29-2
  TTD Drug ID: DMA3OWI

Molecule-Related Drug Atlas

Drug(s) Targeting Arachidonate 5-lipoxygenase activating protein (FLAP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DG031	DMO3AJS	Asthma	CA23	Discontinued in Phase 3	[4]
GSK2190915	DM89AV2	Asthma	CA23	Discontinued in Phase 2	[5]
AM103	DMAQNBW	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 2	[6]
GSK2190914	DMHZQ0T	Asthma	CA23	Discontinued in Phase 2	[7]
A-93178	DM1KBAY	Allergy	4A80-4A85	Terminated	[8]
L-671,480	DMP4QCJ	Discovery agent	N.A.	Investigative	[9]
L-689,037	DMCH3ZK	Discovery agent	N.A.	Investigative	[2]

Drug(s) Targeting Epidermal growth factor receptor (EGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[10]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[11]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[12]
Erlotinib	DMCMBHA	Adrenal gland neoplasm		Approved	[13]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[14]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[15]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[16]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[17]
Epidermal growth factor	DMVONE6	Vulnerary	ND56.Z	Approved	[15]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[5]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Arachidonate 5-lipoxygenase activating protein (FLAP)	TTDMBF5	AL5AP_HUMAN	Inhibitor	[2]
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Inhibitor	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024847)
• [2] 5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors. Mol Pharmacol. 1992 Feb;41(2):267-72.
• [3] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [4] BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
• [5] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [6] AM103 Experimental Treatment for Respiratory Diseases. Amira Pharmaceuticals/GSK. 2009.
• [7] FLAP inhibitors for the treatment of inflammatory diseases. Curr Opin Investig Drugs. 2009 Nov;10(11):1163-72.
• [8] Characterization of A-93178, an iminoxy-quinoline inhibitor of leukotriene biosynthesis. Adv Exp Med Biol. 1997;433:91-4.
• [9] 5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors. Mol Pharmacol. 1991 Jul;40(1):22-7.
• [10] Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
• [11] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [12] Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
• [13] Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
• [14] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [16] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [17] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.